| Carcinoma in situ of bladder
Anktiva vs Adstiladrin
Side-by-side clinical, coverage, and cost comparison for carcinoma in situ of bladder.Deep comparison between: Anktiva vs Adstiladrin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAdstiladrin has a higher rate of injection site reactions vs Anktiva based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Adstiladrin but not Anktiva, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Anktiva
Adstiladrin
At A Glance
Intravesical instillation
Weekly
IL-15 receptor agonist
Intravesical instillation
Every 3 months
IFN-alpha2b gene therapy
Indications
- Carcinoma in situ of bladder
- Carcinoma in situ of bladder
Dosing
Carcinoma in situ of bladder - Induction 400 mcg administered intravesically with BCG once weekly for 6 weeks; a second induction course may be administered if complete response is not achieved at month 3.
Carcinoma in situ of bladder - Maintenance 400 mcg administered intravesically with BCG once weekly for 3 weeks at months 4, 7, 10, 13, and 19; for patients with ongoing complete response at month 25 and later, additional instillations once weekly for 3 weeks at months 25, 31, and 37.
Carcinoma in situ of bladder 75 mL at a concentration of 3 x 10^11 vp/mL instilled intravesically once every 3 months via urinary catheter, retained in the bladder for 1 hour; premedication with an anticholinergic is recommended before each instillation.
Contraindications
—
- Prior hypersensitivity reactions to interferon alfa or to any component of the product
Adverse Reactions
Most common (>=15%) increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills, pyrexia
Serious hematuria, cardiac arrest (fatal in 1 patient)
Most common (>10%) Instillation site discharge, fatigue, pyrexia, chills, bladder spasm, micturition urgency, hematuria, dysuria; laboratory abnormalities (>15%): glucose increased, triglycerides increased, creatinine increased, phosphate decreased, hemoglobin decreased
Serious Coronary artery disease, hematuria
Pharmacology
IL-15 receptor agonist; binds the heterotrimeric IL-15 receptor complex (gamma-c, beta-c, and IL-15Ralpha subunits) on CD4+ and CD8+ T cells and NK cells, driving proliferation and activation of NK, CD8+, and memory T cells without expanding immunosuppressive Treg cells.
Non-replicating adenoviral vector-based gene therapy that delivers a transgene encoding human interferon alfa-2b (IFN-alpha2b) to bladder urothelium, resulting in transient local IFN-alpha2b expression with anticipated anti-tumor effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Anktiva
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Adstiladrin
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Anktiva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Adstiladrin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Anktiva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Adstiladrin
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Anktiva.
$100
Adstiladrin Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AnktivaView full Anktiva profile
AdstiladrinView full Adstiladrin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.